Wei Zhou

6PUBLICATIONS

52CO-AUTHORS

Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 17, 2026

Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance.

|Jul 14, 2025

Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.

Hao Nie, Liping Liao, Rafal J Zielinski

|Apr 02, 2024

Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.

Hao Nie, Pratima Saini, Taito Miyamoto

|Dec 08, 2023

Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.

Rui Fu, Borui Zhao, Min Chen

|Jun 28, 2023

Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer.

Simona Lombardi, Aaron R Goldman, Hsin-Yao Tang

|Jun 21, 2022

KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.

Heng Liu, Jianhuang Lin, Wei Zhou

Pageof 1

Frequent Collaborators

Rugang Zhang

Heng Liu

Andrew V Kossenkov

Yuan Qi

Jianhuang Lin

Daniel T Claiborne

Ronny Drapkin

Benjamin G Bitler

Hsin-Yao Tang

Aaron R Goldman

Frequent Collaborators

Rugang Zhang

Heng Liu

Andrew V Kossenkov

Yuan Qi